Russian Pharma Imports Show Growth

Russia’s pharmaceutical imports stood at $10.8bn in 2017 — a 22% climb on the previous year.

Imports consisted largely (77.5%) of retail-ready therapeuticals and prophylactics, worth $8.4bn, followed by blood and blood fractions for therapeutic and prophylactic purposes, immunity serums and vaccines, which accounted for 16.4% of the imports and were worth $1.8bn.

The third largest group of imports included dental filling materials, which Russia imported to $404.6m and which made 3.7% of the total imports, followed $185.7m’s worth of therapeuticals and prophylactics not destined for hospital use, which made 1.7%.

Dressing supplies, worth $56.9m, made 0.5% of the total imports.

The remaining 0.1% worth $11.6m included glands and other organs, including dried and powdered, gland extractions, heparin and its salts and other therapeuticals of animal and human origin.

Russia’s key suppliers of pharmaceuticals in 2017 were Germany, which accounted for 20.8% of the total imports, France (8.7%), Italy (6%), the United States (5.7%), the United Kingdom (5.5%), India (5.2), Switzerland (5.1), Hungary (4%), the Netherlands (3.5% %), Slovenia (3.5%), and Ireland (2.9%).